论文部分内容阅读
目的探讨低分子肝素钠治疗儿童过敏性紫癜(HSP)的临床效果。方法将48例首次发作HSP病儿,随机分为低分子肝素钠治疗组24例和常规治疗组24例,常规治疗组用大剂量维生素C、双嘧达莫、西咪替丁、葡萄糖酸钙治疗,低分子肝素钠治疗组在此基础上加用低分子肝素钠静脉滴注治疗,观察并比较两组疗效、皮疹消退时间。结果低分子肝素钠治疗组的皮疹消退时间明显短于常规治疗组(P<0.05);随访6个月后,治疗组紫癜性肾炎发生率较对照组明显降低。结论加用低分子肝素钠静脉滴注治疗HSP,预防紫癜性肾炎疗效显著,且安全、可靠,无明显不良反应。
Objective To investigate the clinical effect of low molecular weight heparin on children with Henoch-Schonlein purpura (HSP). Methods Forty-eight children with first-episode HSP were randomly divided into low-molecular-weight heparin group (24 cases) and conventional treatment group (24 cases). The patients in routine treatment group were given high-dose vitamin C, dipyridamole, cimetidine, calcium gluconate Treatment, low molecular weight heparin treatment group based on the addition of low molecular weight heparin sodium intravenous infusion treatment, observe and compare the two groups curative effect, rash subsided time. Results Low molecular weight heparin sodium treatment group rash subsided time was significantly shorter than the conventional treatment group (P <0.05); 6 months follow-up, the treatment group purpura nephritis incidence was significantly lower than the control group. Conclusion Addition of low molecular weight heparin intravenous drip treatment of HSP, prevention of purpura nephritis significant effect, and safe, reliable, no significant adverse reactions.